Division of Hematology News and Updates

1 - 10 of 59

FDA Approves Two Gene Therapies for Sickle Cell Disease

Published on

FDA Approves First CRISPR-Based Therapy for Sickle Cell Disease

The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease  in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 


Pages